Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHACAINE HYDROCHLORIDE vs METRONIDAZOLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.
After entry into the cell, metronidazole is reduced by bacterial nitroreductases to form toxic metabolites that damage DNA and inhibit nucleic acid synthesis, leading to cell death.
Local anesthesia by infiltration or nerve block,Spinal anesthesia,Epidural anesthesia
Trichomoniasis,Bacterial vaginosis,Amebiasis,Giardiasis,Anaerobic bacterial infections (e.g., intra-abdominal, gynecologic, skin and soft tissue, bone and joint, CNS infections),Helicobacter pylori eradication (in combination therapy),Perioperative prophylaxis for colorectal surgery,Acute diverticulitis,Crohn's disease (off-label),Rosacea (topical),Decubitus ulcers (topical)
1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).
500 mg intravenously every 8 hours or 500 mg orally every 8 hours; for bacterial vaginosis, 500 mg orally twice daily for 7 days; for trichomoniasis, 2 g orally as a single dose.
Terminal half-life 2.5-3.5 hours in adults; prolonged to 4-6 hours in hepatic impairment or elderly.
8 hours (range 6-10 hours) in adults; prolonged to 18-20 hours in severe hepatic impairment; requires adjustment in cirrhosis.
Hydrolyzed by plasma pseudocholinesterases to para-aminobenzoic acid and diethylaminoethanol.
Hepatic metabolism via oxidation and glucuronidation; major cytochrome P450 enzymes: CYP2A6, CYP3A4, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1; also reduced by nitroreductases in some bacteria and human cells.
Primarily renal excretion of unchanged drug and metabolites (70-80%); minor biliary elimination (10-15%); fecal excretion <5%.
Renal (60-80% unchanged drug), biliary/fecal (6-15% as metabolites, <20% unchanged).
90-95% bound to alpha-1-acid glycoprotein and albumin.
<20% bound to plasma proteins (albumin).
Vd 0.8-1.2 L/kg; extensive tissue distribution (liver, lungs, brain).
0.7-1.1 L/kg; Vd increased in edema/ascites; distributes widely including CNS, bone, and abscess cavities.
Oral: 30-40% (first-pass metabolism); Intramuscular: 85-95%; Intravenous: 100%.
Oral: 80-95% (100% for immediate-release); Topical: <2% systemic; Vaginal: 20-25% systemic after 500 mg dose.
No specific dose adjustment required; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation. Monitor for CNS toxicity.
For GFR 10-50 m L/min: no adjustment needed; for GFR <10 m L/min: extend interval to every 12 hours if using multiple doses; for intermittent hemodialysis: administer dose after dialysis on dialysis days.
Child-Pugh Class A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or use alternative agent.
For Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: use with caution, consider further dose reduction (e.g., 50% of normal dose every 12 hours) and monitor for toxicity.
Local infiltration: 0.5–2% solution, maximum 4.5 mg/kg (without epinephrine) or 7 mg/kg (with epinephrine). For nerve blocks: weight-based dosing, not to exceed adult maximum.
Neonates: 15 mg/kg loading dose, then 7.5 mg/kg every 12 hours for <7 days, or every 8 hours for 7-28 days; Infants and children: 7.5 mg/kg every 6 hours (max 4 g/day) for most infections; for amebiasis: 35-50 mg/kg/day in 3 divided doses for 10 days.
Reduce total dose by 20–30% due to decreased clearance and increased sensitivity; monitor for prolonged effect and toxicity.
No specific dose adjustment based solely on age, but monitor renal function; reduce dose if creatinine clearance <10 m L/min as per renal adjustment; use lowest effective dose and monitor for neurotoxicity (e.g., peripheral neuropathy, seizures).
Not available.
Carcinogenicity has been observed in mice and rats following chronic administration; however, the relevance to humans is unclear.
Risk of systemic toxicity if absorbed into circulation,Hypersensitivity to ester-type anesthetics,Potential for methemoglobinemia with high doses,Use with caution in patients with impaired cardiac or hepatic function
May cause peripheral neuropathy and CNS effects including seizures, dizziness, and ataxia; discontinue if abnormal neurologic signs occur.,Carcinogenicity in animal studies; use for shortest duration necessary.,Hepatotoxicity and pancreatitis reported.,Hypersensitivity reactions including Stevens-Johnson syndrome.,May prolong QT interval; use with caution in patients with electrolyte disturbances or taking other QT-prolonging drugs.,Potential for disulfiram-like reaction with alcohol; avoid during therapy and for at least 48 hours after completion.,Possible mutagenicity; avoid use in pregnancy (especially first trimester) unless clearly needed.,May cause metallic taste, nausea, and other GI disturbances.
Hypersensitivity to ester-type anesthetics or para-aminobenzoic acid,Severe hypotension,Bleeding disorders (for spinal/epidural use),Infection at the injection site
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (theoretical risk, though risk appears low),Concomitant use with disulfiram (can cause acute psychosis/confusion),Concomitant use with ethanol or propylene glycol (disulfiram-like reaction)
No known food interactions. Avoid excessive grapefruit or grapefruit juice consumption due to potential CYP3A4 inhibition.
Avoid alcohol and alcohol-containing foods (e.g., sauces, vinegars, some desserts) during therapy and for 48 hours after completion. No other significant food interactions.
Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in first trimester if possible.
Metronidazole crosses the placenta. First trimester: limited human data show no consistent increase in major malformations; however, some studies suggest a possible small risk of oral clefts. Second/third trimester: generally considered low risk; no known fetal toxicity at standard doses. Avoid high doses in first trimester unless essential.
Excreted in breast milk in low amounts; M/P ratio not established. Consider risk-benefit; monitor infant for central nervous system depression.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9. Peak milk concentration occurs 2-4 hours after dose. After single 2 g dose, withholding breastfeeding for 12-24 hours is recommended. Chronic use: monitor infant for diarrhea, candidiasis, or irritability.
No specific dose adjustments required; pharmacokinetics may be altered but clinical significance unclear.
No specific dose adjustment required in pregnancy; pharmacokinetics unchanged. Standard adult dosing applies. For bacterial vaginosis: 500 mg PO BID x 7 days or 2 g single dose. Avoid high-dose regimens (e.g., for trichomoniasis) in first trimester; use clotrimazole locally if possible.
Alphacaine Hydrochloride is an amide-type local anesthetic similar to lidocaine. Onset of action is 2-5 minutes with duration of 30-120 minutes depending on concentration and use of epinephrine. It is hepatically metabolized (CYP3A4) and renally excreted. Dose adjustment required in hepatic impairment. Risk of methemoglobinemia, especially in infants and patients on sulfonamides. Do not exceed maximum doses: 4.5 mg/kg plain, 7 mg/kg with epinephrine.
Metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and protozoa. It requires acidic environment for activation; thus, avoid concurrent use with antacids or H2 blockers. Monitor for peripheral neuropathy and seizure with prolonged use. Disulfiram-like reaction occurs with alcohol; counsel patients to avoid alcohol during therapy and for 48 hours after last dose. Use caution in hepatic impairment (dose reduction recommended). Intravenous form is irritant; do not co-administer with blood products via same line.
Avoid alcohol consumption for 24 hours after procedure.,Inform your doctor if you have liver disease, heart block, or history of methemoglobinemia.,Do not drive or operate machinery until effects wear off.,Report numbness, tingling, or twitching immediately.,For dental procedures: avoid eating until numbness resolves to prevent injury.
Avoid alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, and flushing.,Take with food to minimize gastrointestinal upset.,Complete the full course even if symptoms improve.,Report numbness, tingling, or seizures immediately.,May cause metallic taste (harmless) and darkening of urine (not clinically significant).
No interactions on record
"Metronidazole is a known inhibitor of CYP3A4, the primary enzyme responsible for metabolizing Osimertinib. Coadministration increases Osimertinib AUC by approximately 30-60%, leading to elevated plasma concentrations that may potentiate adverse effects such as QTc prolongation, interstitial lung disease, and diarrhea. Clinicians should monitor for signs of Osimertinib toxicity and consider dose reduction if concurrent use is unavoidable."
"Metronidazole inhibits CYP3A4, the primary enzyme responsible for the metabolism of ergotamine. Co-administration can lead to significantly elevated ergotamine plasma concentrations, increasing the risk of ergotism—a serious condition characterized by severe vasoconstriction, ischemia, and potential gangrene of the extremities. Patients may present with symptoms such as cold, painful extremities, muscle pain, and paresthesias, requiring immediate intervention."
"Levofloxacin and metronidazole both prolong the QT interval, and their concurrent use can lead to additive effects on cardiac repolarization. This increases the risk of torsade de pointes, a potentially fatal ventricular arrhythmia. Patients with pre-existing QT prolongation, electrolyte disturbances, or bradycardia are at higher risk."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHACAINE HYDROCHLORIDE vs METRONIDAZOLE, answered by our medical review team.
ALPHACAINE HYDROCHLORIDE is a Local Anesthetic that works by Local anesthetic that reversibly blocks sodium ion channels in neuronal membranes, preventing the generation and propagation of action potentials.. METRONIDAZOLE is a Nitroimidazole Antibiotic that works by After entry into the cell, metronidazole is reduced by bacterial nitroreductases to form toxic metabolites that damage DNA and inhibit nucleic acid synthesis, leading to cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHACAINE HYDROCHLORIDE and METRONIDAZOLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHACAINE HYDROCHLORIDE is: 1–2% solution via local infiltration or nerve block, up to a maximum of 4.5 mg/kg (or 300 mg) without epinephrine; with epinephrine, maximum 7 mg/kg (or 500 mg).. The standard adult dose of METRONIDAZOLE is: 500 mg intravenously every 8 hours or 500 mg orally every 8 hours; for bacterial vaginosis, 500 mg orally twice daily for 7 days; for trichomoniasis, 2 g orally as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHACAINE HYDROCHLORIDE and METRONIDAZOLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHACAINE HYDROCHLORIDE is classified as Category C. Alphacaine hydrochloride is a local anesthetic; limited human data but animal studies show no teratogenicity at clinically relevant doses. Fetal risk cannot be excluded; avoid in f. METRONIDAZOLE is classified as Category A/B. Metronidazole crosses the placenta. First trimester: limited human data show no consistent increase in major malformations; however, some studies suggest a possible small risk of o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.